Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Date:8/21/2007

. MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; a sirtuins program for cancer; and a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of product candidates, including MGCD0103, to demonstrate safety and efficacy in clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical products and new therapies; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; failure of third-party manufacturers to produce the product volumes required
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Optimer Pharmaceuticals, Inc. (Nasdaq: ... the 28th Annual J.P. Morgan Healthcare Conference at ... on Wednesday, January 13, 2010. Michael N. Chang, ... at 2:30 p.m. Pacific Time (5:30 p.m. Eastern ... live audio webcast of this presentation will be ...
(Date:12/16/2009)... CHICAGO, Dec. 16 Advanced Life Sciences ... positive top-line results from a pivotal, non-human primate ... (cethromycin) against an inhaled lethal dose of tularemia. ... survival rate at the doses tested. All ... received 16 mg/kg once-a-day of Restanza (approximate to ...
(Date:12/15/2009)... 15 Warner Chilcott plc (Nasdaq: ... Chilcott Corporation (the "Company") has commenced a cash ... the conditions set forth in the Company,s Offer ... 15, 2009 (the "Offer to Purchase"), for any ... notes due 2015 (the "Notes"). ,, The Company ...
Breaking Medicine Technology:Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 3Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 2Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 3Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 6Repligen to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference Wednesday September 9th 2 3A25 p m EDT 13791 1Repligen to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference Wednesday September 9th 2 3A25 p m EDT 13791 2Repligen to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference Wednesday September 9th 2 3A25 p m EDT 13791 3Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 1Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 2Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 3Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 4Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 5September 2009 is Atrial Fibrillation Month 55975 1September 2009 is Atrial Fibrillation Month 55975 2
(Date:12/16/2009)... -- Sermo ( http://www.sermo.com ), the world,s largest ... of a new Sermo Vitals Report titled " ... report examines physician dialog about diabetes over a ... a variety of topics, including the therapies physicians ... candid/verbatim comments on issues related to diabetes. ...
(Date:12/16/2009)... now than in the ,70s, study finds , , TUESDAY, ... common in the United States than it was more ... shows. , Researchers compared National Health and Nutrition Examination ... 1971 to 1972 and from 8,339 black and white ... to 54 years old. , The prevalence of myopia ...
(Date:12/16/2009)... County area dry cleaner Dryclean USA donates time and money to ... ... (PRWEB) Dec. 16, 2009 -- South Florida dry cleaner Dryclean ... with the charity Prints of Hope to help clothe ... needy families. Dryclean USA Florida will begin distributing cards, with ...
(Date:12/16/2009)... has been brought into reach for many Houstonians with the announcement ... , ... (PRWEB) December 16, 2009 -- The cost ... with the announcement by Hearing Haven, LLC of a new subscription ... the job, and want to improve communications and relationships with family ...
(Date:12/16/2009)... EncorePath, Inc., a company engaged in the development of products ... brain injury to improve mobility, announces the publication of an ... stroke rehabilitation, the Tailwind. (Advance for Physical Therapy and Rehab ... Lauren Fitzky). , ... (PRWEB) ...
Breaking Medicine News(10 mins):Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 2Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 3Health News:Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations 2Health News:Monthly Subscription Hearing Aid Plan Announced for Houston 2Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2
... Mo. -- Each year, pharmaceutical companies invest millions of dollars ... market because of side effects found only during human clinical ... for organ transplants continues to increase. In the past 10 ... led by a University of Missouri-Columbia physics researcher might present ...
... Diagnostics, Tissue of Origin Test Designed to Aid in ... Determination of a ... a,genomics-based diagnostics company focused on oncology, announced today,that Virginia Commonwealth ... Pathwork(TM) Tissue of Origin Test. The new,genomics-based test is designed ...
... diabetes to enter art contest ... kids in the U.S., INDIANAPOLIS, Nov. 6 Al ... the Inspired by,Diabetes global campaign as a National Ambassador to ... Inspired by Diabetes is a global collaboration among Eli Lilly ...
... NACO ART Centers, Group Provides Patients Free,Second-line ART, ... Healthcare,Foundation (AHF), which operates free AIDS treatment clinics ... and support services to over,5,000 Indian clients, is ... providing,lifesaving second-line antiretroviral treatment (ART) free to Indian ...
... centers throughout the country provide acute care to patients ... physical injury of the patients; there is precious little ... gave rise to the injury or to what its ... oral and maxillofacial surgeon at the UCLA School of ...
... in danger, study suggests , , TUESDAY, Nov. 6 (HealthDay ... rate and could pose risks to people with hypertension ... They found that drinking two cans of a popular ... 15 healthy adults, average age 26. , Within a ...
Other Medicine News:Health News:MU research team makes progress toward 'printing' organs 2Health News:MU research team makes progress toward 'printing' organs 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 2Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 2Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 3Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 5Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 6Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 2Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 3Health News:NIH grant advances dentistry school's work on psychosocial stress 2Health News:NIH grant advances dentistry school's work on psychosocial stress 3Health News:Energy Drinks Could Pose Blood Pressure Risks 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: